Enovis Corp Earnings Call Highlights Growth and Cash

Enovis Corporation ((ENOV)) has held its Q4 earnings call. Read on for the main highlights of the call.

Enovis Corporation’s latest earnings call struck a broadly upbeat tone, with management emphasizing solid organic growth, strong Recon momentum, expanding gross margins and a return to positive free cash flow. Concerns centered on a large noncash goodwill impairment, tariff pressures and some Q4 execution issues, but executives argued these do not derail the company’s improving fundamental trajectory.

Steady Full-Year Growth Led by Recon and P&R

Enovis reported 2025 sales of $2.2 billion, up 7% on a reported basis and 6% organically, underscoring healthy underlying demand across its portfolio. Recon led the way with 8% organic growth while Prevention & Recovery delivered 4% growth, giving the company a balanced growth profile across its major segments.

Q4 Revenue Softness Skewed by Fewer Selling Days

Fourth-quarter revenue came in at $576 million, rising 3% reported and 2% organically versus the prior year. Management stressed that four fewer selling days in Q4 created roughly a 400-basis-point drag on organic growth, masking what they believe was stronger underlying performance.

Recon Segment Delivers Robust U.S. and International Gains

In Recon, U.S. organic growth reached 6%, fueled by double-digit gains in extremities and strong shoulder performance anchored by the ARG platform. International Recon grew an even faster 10% organically, supported by high single-digit growth in hips and knees and double-digit growth in extremities, signaling global share capture.

Innovation Pipeline Accelerates with New Launches

Enovis highlighted a surge in innovation, including the 2025 launches of the Nebula Stent and OrthoDrive Impactor, with Nebula already drawing more than 60% of its sales from competitive conversions. The company also achieved 50% more 510(k) clearances than its prior best year and plans a flexible rollout of Arvis at AAOS, underscoring a strong pipeline for the next 24 months.

Margins Expand as Profitability Continues to Improve

Adjusted gross margin rose to 61%, an improvement of 170 basis points year over year, reflecting better mix and productivity. Adjusted EBITDA margin held around 17.9% despite headwinds, and adjusted EPS climbed 16% to $3.30, showcasing disciplined cost control alongside growth investments.

Free Cash Flow Turns Positive and Balance Sheet Strengthens

After a difficult prior year, Enovis generated $20 million of free cash flow in 2025, converting 10% of adjusted net income versus negative 43% previously. The company lowered leverage to 3.1 times, cut interest expense to $35 million from $57 million and refinanced its term loan while upsizing its revolver, improving financial flexibility.

Portfolio Shaping Fuels Faster P&R Momentum

The Prevention & Recovery segment accelerated to about 4% organic growth for the year, roughly twice the market pace according to management. BoneStim, Manafuse and LiteCure posted double-digit gains, and after portfolio shaping including the Dr. Comfort sale, about half of P&R revenue is now growing faster than mid-single digits.

Significant Goodwill Impairment Weighs on Headline Results

Enovis recorded a noncash goodwill impairment of $501 million in Q4 2025 after comparing its market capitalization with carrying values. Management emphasized that this accounting charge does not affect liquidity, cash flows or debt covenants, but it remains a notable hit to reported earnings and a focus point for investors.

Q4 Execution Miss and Calendar Effects Temper Momentum

Beyond the lost selling days, executives acknowledged execution shortcomings in the fourth quarter, with organic growth limited to 2% and P&R flat in the period. They framed these as near-term operational issues rather than structural problems but recognized that investors will be watching for cleaner execution in the coming quarters.

Tariff and Cost Pressures Cap Margin Upside

Tariffs represented roughly $15 million of costs in 2025, diluting results and limiting the ability to expand adjusted EBITDA margin despite internal productivity gains. Management suggested that while mix and efficiency initiatives are helping, these external cost headwinds remain a constraint on faster margin expansion.

Revenue Drag from Dr. Comfort Divestiture

The October 2025 sale of Dr. Comfort is expected to create a roughly $41 million revenue headwind in 2026. Enovis argues that this portfolio move sharpens the company’s focus and improves growth quality, even as it modestly suppresses top-line growth in the near term.

Seasonality and Operational Risks Cloud the Near Term

Management cautioned that weather-related disruptions and softer elective procedures are likely to pressure first-quarter results. The 2026 calendar also has two fewer selling days in Q1 and faces tough comparisons against 2025, which could make early-year organic growth appear muted despite underlying demand.

Integration and Investment Spending to Remain Elevated

Enovis expects another substantial year of spending to complete the Lima integration and ramp up R&D, including enabling technologies in Recon and the Arvis rollout. These investments may limit near-term margin and cash flow expansion, but management views them as essential to sustaining competitive differentiation and long-term growth.

Guidance Points to Continued Growth and Cash Progress

For 2026, Enovis guided revenue to $2.31–$2.37 billion, implying 4%–6% organic growth driven by high single-digit Recon and low single-digit P&R, with minor FX tailwinds and the Dr. Comfort revenue drag. The company targets adjusted EBITDA of $425–$435 million with about 50 basis points of margin improvement, adjusted EPS of $3.52–$3.73, free cash flow conversion of at least 25% and ongoing deleveraging toward below 3 times.

Enovis’s earnings call portrayed a company leaning into growth and innovation while tightening its balance sheet and gradually improving margins. While the sizable goodwill impairment, tariffs, integration costs and near-term execution risks warrant monitoring, the underlying trends in Recon, P&R and cash conversion suggest a steadily improving story for long-term shareholders.